The generation, evaluation, and presentation of data from the ILSI Alternatives to Carcinogenicity Testing (ACT) program was standardized to ensure that the results of studies performed in multiple laboratories could be reliably compared. To this end, standardized experimental protocols, tissue collection procedures, histopathology nomenclature, diagnoses, and terminology were employed by study participants. In the experimental phase, this approach provided important cross-model consistency. To ensure comparability in the data evaluation phase of the project, interpretive criteria were de ned to allow the characterization of study outcome as positive, negative, or equivocal in regards to carcinogenic response. These criteria helped to provide consistency across models because separate Assay Working Groups were established to evaluate the results of each model. To organize and compile the data from the ILSI ACT program, a database has been developed and data entered in standardized format to facilitate cross-and intramodel comparisons. In summary, the early development of standardized test protocols, evaluation procedures, and interpretive criteria has resulted in a data set in which users can have a high level of assurance that results in the database re ect consistently applied experimental and interpretive guidelines.
INTRODUCTION
All phases of study design and execution are important components for producing reliable and therefore usable scienti c data. However, the method for evaluating study data can make the difference between producing information of questionable value versus information that can be reliably used for decision making. This issue was particularly important to address in the ILSI Alternative Carcinogenicity Testing (ACT) program because studies were performed in multiple laboratories, each with their own internal procedures and historical perspectives to the evaluation of toxicology studies. Because the value of the ILSI ACT program is largely dependent on comparing results across laboratories, it was important that standardized criteria for evaluation of the results be established and utilized in the evaluation. This need for standardized experimental execution and data evaluation was recognized early in the planning phase of the ACT program and resulted in the development of several experimental and interpretive guidelines for purposes of this project.
Approach to Histopathological Consistency
The need for standardization of pathology terminology and processes has been widely recognized for a number of years (4) . To be certain that the ILSI ACT program was applying current and standardized approaches for all studies, a Pathology Subcommittee was established ( Table 1) to develop several guidelines that were distributed to the participating laboratories.
Tissue Selection: The decision to examine one area of an organ versus another can greatly impact the histological observation and resultant experimental conclusions. Standardized procedures for selecting and examining tissues are important for consistency of data. There are a number of examples where lesions are not uniformly represented in various parts of an organ as might be expected. The number of tissue blocks, the orientation of these blocks in relation to the whole organ, and the quantity of tissue examined can impact the detection of relatively small microscopic tumors (1) . The greater the amount of tissue that is examined, the greater the probability that a limited number of small lesions may be identi ed. To address these issues, the Pathology Subcommittee recommended the "Tissue Trimming Scheme" developed by the Registry of Industrial Toxicology Animal Data (2) that clearly outlined guidelines for the selection of tissues for histologic evaluation. These tissue trimming guidelines were developed through a consensus process and were largely parallel to tissue selection procedures generally utilized in the performance of regulatory toxicology studies. This approach provided for a standardization of sectioning of tissues across the numerous ILSI ACT studies and also provided a reasonable basis for comparison to results that have been generated in traditional 2-year carcinogenicity studies.
Terminology: The ability to compare tumor data across studies is also dependent on the use of standardized terminology. If a comparable lesion is denoted by 2 different terms in the database for the ILSI ACT studies, the ability to compare these results is seriously hindered if not totally eliminated. To make certain that standardized terms were used to the greatest degree that lesion morphology permits, the Pathology Subcommittee recommended that all pathologists evaluating histologic material in the ILSI ACT program should follow the "Guideline for Toxicologic Pathology" (3) as developed and published by the Society of Toxicologic Pathologists (STP). Alternatively, pathologists were advised to use the "International Classi cation of Rodent Tumors" (4) that has been published by the International Agency for Cancer Research (IARC). These two widely used and peer-reviewed documents contain substantially similar recommendations for use of diagnostic terms. 20 0192-6233/01$3.00 $0.00 Speci cally, the two guidelines for histologic nomenclature provide recommended diagnostic terms in conjunction with histologic descriptions and photographs illustrating the salient features of the lesions. In addition, these guidelines provide criteria that assist in the distinction of neoplastic from hyperplastic lesions. Consistent application of this distinction is essential so that cross-study comparisons of incidence of neoplasms are real and not based on differences in the diagnostic criteria used to de ne a neoplasm.
Peer Review: Pathology peer review has been incorporated into the process of histologic evaluation of most, if not all, studies that are submitted to regulatory agencies. Peer review provides assurance of the quality of the histologic data used to determine the effects in animals. Perhaps most importantly, peer review assures that lesions have been identi ed and that a standardized use of diagnostic terminology has been applied to the evaluation of a study. Therefore, the Pathology Subcommittee (Table 1) recommended that pathology peer review should be included in the process of reaching a nal diagnoses in the ILSI ACT studies.
Routine pathology peer review applied in each of the participating laboratories formed the primary basis for assuring the quality of the histologic diagnosis. The ILSI ACT program also established a system to address unusual lesions that were not readily covered by the standard nomenclature guides noted previously. Such lesions were anticipated as unusual pathology pro les have been noted in a number of transgenic animals in recent years. To assure a process for standardization of nomenclature for these unusual lesions, a pathology consultant system was established within the ILSI ACT program. When an unusual lesion was identi ed by a pathologist in one of the participating laboratories, a pathologist that was assigned as a coordinator for that animal model was noti ed. This Assay Working Group Pathologist had the responsibility to poll other pathologists working with that model to determine if similar unusual lesions may have been identi ed at other laboratories. The pathologist would circulate slides and call for teleconference discussions as required. There were several instances where unusual lesions were identi ed but the diagnosis was successfully agreed upon through the coordination of the Assay Working Group Pathologist via the process just described.
Although histopathology is the primary basis for assessing tumor responses in classic 2-year carcinogenicity studies and in the majority of the models used in the ILSI ACT program, evaluation of the response in the Tg.AC model used in the ACT program is primarily dependent on the gross observation of skin surface tumors. This approach is consistent with the evaluation of skin tumor responses as evaluated in classic skin "painting" protocols for the evaluation of carcinogenicity. In the Tg.AC model studies, papillomas were observed and at de ned time points counted throughout the study. For a lesion to be considered in the nal assessment of a tumor response, the grossly observed lesion had to reach a diameter of 1 mm and persist for a minimum of 2 weeks. The maximum number of tumors noted at any single observation period was the value used in the determination of a response. The maximal number of tumors enumerated and tracked was twenty.
The histopathology tumor data (or in the case of the Tg.AC model, the number of tumors noted grossly) were recorded in a toxicology study report similar to the presentation of data in a 2-year bioassay study to evaluate carcinogenicity. As described next, upon review and approval by the Assay Working Groups, the tumor data were entered into the ILSI ACT Database by the participating laboratory personnel.
Evaluation of Results from Individual Studies
Evaluation of the study results is a critical step in determining the presence or absence of a neoplastic response in any carcinogenicity testing program. In the case of the ILSI ACT program, the evaluation of studies took on additional importance because the goal of the program was to compare results across compounds evaluated within a single model as well as to evaluate results for a single compound across models. To assure the validity of these comparisons, it was essential that the analysis of the data be standardized.
Each participating laboratory in the ILSI ACT program was responsible for the initial evaluation of the data generated by that laboratory. This interpretation was included in the study report. The study reports were circulated to members of the relevant Assay Working Group for review prior to a meeting or conference call held to discuss the adequacy of the study and to evaluate the interpretation of the study results. The Assay Working Group review resulted in either approval of the study or a request for clari cations (eg, additional information on the data or study performance parameters). Communicated approval of the Assay Working Group Chairperson provided the basis for inclusion of the data into the ILSI ACT Database (discussed below). This review of information entering into the database assured consistency of the evaluation and provided a check on the rigors of study design and performance.
The Assay Working groups used multiple interpretative criteria to assess the effect of the chemical in a speci c model. 1) Background tumor incidence. Although the incidence of a speci c tumor type in the concurrent control group was the primary basis for evaluation of the response, the background incidence (ie, historical incidence) was also considered. This approach was limited because large historical databases generally did not exist for the models studied in the ILSI ACT program. As the program progressed, the accumulated control data from multiple studies helped to provide a very important perspective on background tumor incidence at the time points relevant for the length of studies outlined in the ILSI protocols. 2) Involvement of multiple tissues. As in the standard 2-year carcinogenicity studies, multiple tissues were evaluated. However, a clear positive response in a single tissue was considered adequate to conclude that there was a positive response in the study. 3) Presence or absence of a dose response. An increased incidence of tumors with increasing dose was considered to provide supportive evidence that the tumors were the result of the chemical administered. The presence or absence of a dose response was particularly important in evaluating minimal increases in tumors.
4) Evidence of biological effect of compound in the test
animal. Expected effects on the tissue such as the induction of hyperplasia and/or hypertrophy were important points used in the evaluation of the compound. Hyperplasia was considered in the overall interpretation of a potential neoplastic response in the studies. 5) Knowledge of the pharmacology/biochemistry of the compound. Many of the test compounds were expected to result in either observable in-life effects or histologic effects in the models tested. The presence or absence of these anticipated responses were important indicators as to whether the study had been satisfactorily performed. The comparison of the predicted response and actual response was particularly important when the study resulted in a lack of a tumor response. 6) Presence of compound related toxicity and/or mortality.
As in standard 2-year bioassays, toxicity and mortality were used as indicators of whether the animals were given doses that approached or exceeded levels that could be tolerated by a particular animal model . 7) Statistical evaluation of tumor incidence in treated and concurrent control animals. To provide guidance for the statistical evaluation of data on the incidence of animals with neoplasms, the Statistics Subcommittee ( 
Interpretive Criteria for De ning Neoplastic Responses
For consistency of interpretation, it was essential to develop a standardized basis for categorizing neoplastic responses across the different models. Therefore, criteria for interpretation were developed by the Steering Committee and considered by the Assay Working Groups that had the respon-sibility to evaluate the results of completed studies. Thus, criteria were de ned for classifying a response as positive, negative, or equivocal as follows.
A positive response was primarily characterized by an incidence of treated animals with neoplasms that was clearly greater than the incidence of animals with tumors in the concurrent control groups and in the available historical control data sets. For rare tumors (de ned as tumors that had a historical control incidence of 1% or less at the end of the assay period), statistical signi cance was not required to identify a positive response. An assessment of rare tumors was also made retrospectively for each model, considering the results across the studies. A positive response generally was identied as a statistically signi cant greater incidence in treated versus control animals for tumors that are common in the model. Additional factors that were considered in assessing a positive response included the presence of hyperplastic lesions that could be reasonably anticipated to represent the early developmental stages of the neoplasm and the results in the opposite sex. However, the response or lack of response in the opposite sex was only considered to be a qualitative indicator.
Identi cation of a negative response was based on multiple criteria. The rst criterion was the lack of a statistically signi cant increased incidence of animals with neoplasms in the treated groups compared to the concurrent control group. A negative response was also characterized as an observed increase in the number of animals with a tumor that was expected based on the spontaneous tumor rate for that model. To provide assurance that a negative response accurately represented a lack of tumorigenic potential for the compound in the model, it was important to have assurance that the performance of the study was adequate. Adequacy of the study was determined by assessing all study parameters. Speci c consideration was given to an evaluation of whether the dose represented either a maximum tolerated dose or a maximum feasible dose. In addition, the Assay Working Group evaluation required that a positive control response be obtained either as part of the study under evaluation or alternatively that a positive control response had been previously obtained in the laboratory.
As in the evaluation of 2-year bioassays, responses in the models evaluated in the ILSI ACT program were not always easily assigned to either a positive or negative category. Therefore, the Steering Committee also identi ed an equivocal response category. This category was used when the available data did not allow classi cation as clearly positive or negative. However, the Assay Working Groups were encouraged to obtain all available information required to make a determination of the response before characterizing an outcome as equivocal.
Because the tumor response in the Tg.AC model relied primarily on the gross observation of papillomas and the evaluation of the numbers of papillomas, criteria in addition to the incidence of tumor bearing animals were considered in evaluating positive, negative, and equivocal responses in this model. These criteria included: time between onset of treatment and the rst appearance of tumors, maximum multiplicity of papillomas expressed during the treatment period, and the time of appearance of maximum multiplicity of papillomas.
Communication of the results of the studies included the designation of positive, negative, or equivocal as de ned previously. To support these conclusions, study sponsors were required to provide a brief statement describing the rationale for the response designations. This information served as a basis to evaluate the consistency of designations of responses and also provides an important historical record to be used in conjunction with any potential re-evaluation of the primary data in the future.
Database for Current and Future Evaluation
The ILSI ACT program created a very large set of data that will serve as a future basis for comparing the effects of speci c compounds in several models. However, this wealth of information provides dif culties and challenges. The need for a central and accessible repository of the information was recognized early in the development of the ILSI initiative. To meet the need, the ILSI ACT Database was initiated. The goal in developing this database was to provide a source of information where the results of all studies would be available in a common format. Such a common format provided the basis for analysis of the study results across studies and models consistent with the original objective of the program. Such comparisons would be seriously hindered if the data from the multiple studies were located only in the individual participating laboratories or if the data were in a centralized location but not in a common format for comparison. The database also provides an important resource of information for the future as additional studies are performed or as additional information becomes available on the speci c models that may suggest additional or alternative interpretations of the original data set.
The ILSI ACT Database has been developed by the Fraunhofer Institute of Toxicology and Aerosol Research in Hannover, Germany. The selection of the Fraunhofer Institute allowed the utilization of existing and proven software systems that were developed for the Registry of Industrial Toxicology Animal-Data (RITA) and ILSI North American Control Animal Database (NACAD). These systems have been under development, re nement, and use in the Fraunhofer Institute for over 10 years. The RITA Database currently includes results of more than 130 studies from approximately 13,000 rats and mice. Because the ILSI ACT Database used previously developed software, a functioning system was available in a relatively short period of time and at a reasonable cost. Although the ILSI ACT Database relies on an existing software system, it was modi ed to meet the needs of the data set developed by the current ILSI initiative. The ILSI ACT Database is housed at the Fraunhofer Institute, but it is important to note that the ILSI ACT Database is independent of other databases at the Fraunhofer Institute.
The ILSI ACT Database includes information on basic study design as well as other relevant factors that may inuence the analysis of the data included. For example, the data for a particular study may indicate if there were any minor differences in study conditions between that study and those to which it might be compared. In-life observations are available in the database and are valuable for cross-study comparisons if toxic or pharmacological effects resulted in clinical signs in the study. Mortality information is available that assists in understanding the cross-group tumor and toxic responses. Organ weight and macroscopic observations noted at necropsy, and histologic diagnoses on all proliferative lesions are also included. Data on these hyperplastic responses were included to provide additional information to assist in the interpretation of minimal neoplastic responses.
Each participating laboratory was responsible for the entry of study data into the ILSI ACT Database. This process was facilitated by a software system developed and provided by the Fraunhofer Institute. As noted previously, data entry into the database occurred only after the Assay Working Group had determined that the study was adequate and that the designation of positive, negative, or equivocal was appropriate. Acceptability of the study was communicated directly by the Assay Working Group Chairperson to the Fraunhofer Institute. This system of approval and communication of approval of the data from a study provided a very important check to ensure the quality and comparability of the data in the database
The rst signi cant use of the database was for purposes of preparation for the public workshop held in Leesburg, Virginia in November, 2000 to discuss the available results of the ILSI ACT program. The database was immediately made open to those organizations that nancially supported the database. From the inception of the project, ILSI has committed to making the database publicly available. The speci cs regarding the mechanism and cost of access to the database are currently being addressed.
